• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过微流控装置合成的载 RNA 脂质纳米粒的粒径调控。

On the size-regulation of RNA-loaded lipid nanoparticles synthesized by microfluidic device.

机构信息

Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, Japan.

Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, Japan.

出版信息

J Control Release. 2022 Aug;348:648-659. doi: 10.1016/j.jconrel.2022.06.017. Epub 2022 Jun 18.

DOI:10.1016/j.jconrel.2022.06.017
PMID:35716883
Abstract

The use of lipid nanoparticles (LNPs) for nucleic acid delivery is now becoming a promising strategy with a number of clinical trials as vaccines or as novel therapies against a variety of genetic and infectious diseases. The use of microfluidics for the synthesis of the LNPs has attracted interest because of its considerable advantages over other conventional synthetic methods including scalability, reproducibility, and speed. However, despite the potential usefulness of large particles for nucleic acid delivery to dendritic cells (DCs) as a vaccine, the particle size of the LNPs prepared using microfluidics is typically limited to approximately from 30 to 100 nm. In this study, focusing on Derjaguin-Landau-Verwey-Overbeek (DLVO) theory, the effect of some synthetic parameters, including total flow rate, flow rate ratio, buffer pH, lipid concentration, molar ratio of PEG-lipid as well as salt concentration, on particle size was systematically examined by means of the design of experiment approaches. The findings indicated that the simple addition of salt (e.g. NaCl) to a buffer containing nucleic acids contributed greatly to the synthesis of large LNPs over 200 nm and this effect was concentration-dependent with respect to the salt. The effect of salt on particle size was consistent with a Hofmeister series. The systemic injection of larger mRNA-loaded LNPs resulted in a higher transgene expression in mouse splenic DCs, a higher activation of various splenic immune cells, and had a superior effect as a therapeutic cancer vaccine in a syngeneic mouse model compared to the smaller-sized counterpart with constant lipid composition prepared with lower NaCl concentration. Collectively, size-regulation by the simple addition of salt is a promising strategy for developing potent LNPs.

摘要

脂质纳米粒 (LNP) 用于核酸递送现在成为一种很有前途的策略,许多临床试验将其用作疫苗或针对各种遗传和传染性疾病的新型疗法。由于其在可扩展性、重现性和速度等方面优于其他传统合成方法,因此使用微流控技术合成 LNPs 引起了人们的兴趣。然而,尽管大颗粒在作为疫苗将核酸递送至树突状细胞 (DC) 方面具有潜在的用途,但使用微流控技术制备的 LNPs 的粒径通常限制在约 30 至 100nm 左右。在这项研究中,我们重点关注德加古因-兰德澳-沃韦尔贝克 (DLVO) 理论,通过实验设计方法系统地研究了一些合成参数(包括总流速、流速比、缓冲液 pH 值、脂质浓度、PEG-脂质的摩尔比以及盐浓度)对粒径的影响。研究结果表明,在含有核酸的缓冲液中简单添加盐(例如 NaCl)极大地有助于合成超过 200nm 的大 LNPs,并且这种效应与盐的浓度有关。盐对粒径的影响与豪夫迈斯特序列一致。较大的 mRNA 负载 LNPs 的全身注射导致小鼠脾脏 DC 中转基因表达更高,各种脾脏免疫细胞的激活更高,并且在同基因小鼠模型中作为治疗性癌症疫苗的效果优于用较低 NaCl 浓度制备的具有恒定脂质组成的较小尺寸的对应物。总的来说,通过简单添加盐进行粒径调节是开发有效 LNPs 的一种很有前途的策略。

相似文献

1
On the size-regulation of RNA-loaded lipid nanoparticles synthesized by microfluidic device.通过微流控装置合成的载 RNA 脂质纳米粒的粒径调控。
J Control Release. 2022 Aug;348:648-659. doi: 10.1016/j.jconrel.2022.06.017. Epub 2022 Jun 18.
2
Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.基于微流控的脂质纳米颗粒粒径控制后处理方法的开发及其在 siRNA 递送中的应用。
ACS Appl Mater Interfaces. 2020 Jul 29;12(30):34011-34020. doi: 10.1021/acsami.0c05489. Epub 2020 Jul 15.
3
Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles.具有 pH 敏感性的阳离子脂质的疏水支架有助于与磷脂混合,并通过小尺寸脂质纳米颗粒提高短干扰 RNA 的递送效率。
Acta Biomater. 2020 Jan 15;102:341-350. doi: 10.1016/j.actbio.2019.11.022. Epub 2019 Nov 13.
4
Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery.载有 siRNA 的小尺寸脂质纳米粒的理化性质和效力的阐明用于 siRNA 的递送。
J Control Release. 2016 May 10;229:48-57. doi: 10.1016/j.jconrel.2016.03.019. Epub 2016 Mar 17.
5
Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning.利用机器学习理解 mRNA 递释用脂质纳米粒的制造工艺。
Chem Pharm Bull (Tokyo). 2024;72(6):529-539. doi: 10.1248/cpb.c24-00089.
6
Importance of Process Parameters Influencing the Mean Diameters of siRNA-Containing Lipid Nanoparticles (LNPs) on the in Vitro Activity of Prepared LNPs.影响载有 siRNA 的脂质纳米颗粒(LNPs)平均直径的工艺参数对所制备 LNPs 体外活性的重要性。
Biol Pharm Bull. 2022;45(4):497-507. doi: 10.1248/bpb.b21-01016.
7
The Effect of Size and Charge of Lipid Nanoparticles Prepared by Microfluidic Mixing on Their Lymph Node Transitivity and Distribution.微流控混合法制备的脂质纳米粒子的大小和电荷对其淋巴结转移和分布的影响。
Mol Pharm. 2020 Mar 2;17(3):944-953. doi: 10.1021/acs.molpharmaceut.9b01182. Epub 2020 Feb 5.
8
mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy.靶向树突状细胞的mRNA负载脂质纳米颗粒用于癌症免疫治疗
Pharmaceutics. 2022 Jul 28;14(8):1572. doi: 10.3390/pharmaceutics14081572.
9
Synthesis of Polymer-Lipid Nanoparticles by Microfluidic Focusing for siRNA Delivery.通过微流体聚焦合成用于siRNA递送的聚合物-脂质纳米颗粒。
Molecules. 2016 Oct 17;21(10):1314. doi: 10.3390/molecules21101314.
10
Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery.基于脂质纳米颗粒的 RNA 递释的微流控技术和装置。
J Control Release. 2022 Apr;344:80-96. doi: 10.1016/j.jconrel.2022.02.017. Epub 2022 Feb 17.

引用本文的文献

1
Machine learning-assisted microfluidic approach for broad-spectrum liposome size control.用于广谱脂质体尺寸控制的机器学习辅助微流控方法
J Pharm Anal. 2025 Jun;15(6):101221. doi: 10.1016/j.jpha.2025.101221. Epub 2025 Feb 3.
2
Lipid nanoparticle delivery of the CRISPR/Cas9 system directly into the mitochondria of cells carrying m.7778G>T mutation in MtDNA (mt-Atp8).将CRISPR/Cas9系统通过脂质纳米颗粒直接递送至线粒体DNA(mt-Atp8)携带m.7778G>T突变的细胞线粒体中。
Sci Rep. 2025 Jun 19;15(1):18717. doi: 10.1038/s41598-025-03671-8.
3
A factorial design-optimized microfluidic LNP vaccine elicits potent magnesium-adjuvating cancer immunotherapy.
一种经析因设计优化的微流控脂质纳米颗粒疫苗引发强效镁佐剂癌症免疫疗法。
Mater Today Bio. 2025 Mar 24;32:101703. doi: 10.1016/j.mtbio.2025.101703. eCollection 2025 Jun.
4
Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches.基于XGBoost/贝叶斯方法和集成模型方法的机器学习驱动的mRNA-脂质纳米颗粒疫苗质量优化
J Pharm Anal. 2024 Nov;14(11):100996. doi: 10.1016/j.jpha.2024.100996. Epub 2024 May 8.
5
RP-CAD for Lipid Quantification: Systematic Method Development and Intensified LNP Process Characterization.用于脂质定量的RP-CAD:系统方法开发与强化LNP工艺表征
Pharmaceuticals (Basel). 2024 Sep 16;17(9):1217. doi: 10.3390/ph17091217.
6
Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA.脂质纳米粒(LNPs)的大小、表面电荷和聚乙二醇化脂质在 mRNA 肌肉内递送中的作用。
J Nanobiotechnology. 2024 Sep 11;22(1):553. doi: 10.1186/s12951-024-02812-x.
7
Supramolecular assembly of polycation/mRNA nanoparticles and in vivo monocyte programming.多阳离子/mRNA 纳米颗粒的超分子组装和体内单核细胞编程。
Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2400194121. doi: 10.1073/pnas.2400194121. Epub 2024 Aug 22.
8
Steering the course of CAR T cell therapy with lipid nanoparticles.用脂质纳米粒引导 CAR T 细胞治疗的方向。
J Nanobiotechnology. 2024 Jun 28;22(1):380. doi: 10.1186/s12951-024-02630-1.
9
Single-Particle Spectroscopic Chromatography Reveals Heterogeneous RNA Loading and Size Correlations in Lipid Nanoparticles.单颗粒光谱色谱法揭示了脂质纳米颗粒中 RNA 负载的异质性和大小相关性。
ACS Nano. 2024 Jun 18;18(24):15729-15743. doi: 10.1021/acsnano.4c02341. Epub 2024 Jun 5.
10
mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model.用于乙型肝炎的mRNA治疗性疫苗在AAV-HBV小鼠模型中显示出免疫原性和疗效。
Vaccines (Basel). 2024 Feb 25;12(3):237. doi: 10.3390/vaccines12030237.